Skip to main content
Infectious Diseases in Obstetrics and Gynecology logoLink to Infectious Diseases in Obstetrics and Gynecology
. 1995;3(1):7–11. doi: 10.1155/S1064744995000238

Comparative Study of the Effectiveness of Oral Fluconazole and Intravaginal Clotrimazole in the Treatment of Vaginal Candidiasis

Hiroshige Mikamo 1,, Koji Izumi 1, Kunihiko Ito 1, Teruhiko Tamaya 1
PMCID: PMC2364408  PMID: 18475414

Abstract

Objective: A study was carried out to compare 3 treatment regimens for vaginal candidiasis.

Methods: A total of 150 women with clinical and mycological evidence of vaginal candidiasis were randomized to receive 50 mg of oral fluconazole daily for 6 days (50 women), a single oral 150 mg dose of fluconazole (50 women), or 100 mg of intravaginal clotrimazole daily for 6 days (50 women). They were assessed at 5–15 days (short-term assessment) and again at 30–60 days (long-term assessment) after the completion of treatment.

Results: Candida species were completely eradicated from the vagina in 88% or 80% in the 6-day oral fluconzaole group, 76% or 70% in the single oral fluconazole group, and 72% or 60% in the intravaginal clotrimazole group at short-term or long-term assessment, respectively. The rates of clinical effectiveness were 92% or 88% in the 6-day oral fluconzaole group, 80% or 76% in the single oral fluconazole group, and 72% or 58% in the intravaginal clotrimazole group at the short-term or long-term assessment, respectively. Treatment-related side effects were not found in any group.

Conclusions: This study suggests that the treatment of vaginal candidiasis with oral fluconazole is effective and that a single oral fluconazole dose might be one choice in the treatment of vaginal candidiasis.

Full Text

The Full Text of this article is available as a PDF (375.1 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bisschop M. P., Merkus J. M., Scheygrond H., Van Cutsem J., van de Kuy A. Treatment of vaginal candidiasis with ketoconazole, a new, orally active, antimycotic. Eur J Obstet Gynecol Reprod Biol. 1979 Aug;9(4):253–259. doi: 10.1016/0028-2243(79)90065-0. [DOI] [PubMed] [Google Scholar]
  2. Humphrey M. J., Jevons S., Tarbit M. H. Pharmacokinetic evaluation of UK-49,858, a metabolically stable triazole antifungal drug, in animals and humans. Antimicrob Agents Chemother. 1985 Nov;28(5):648–653. doi: 10.1128/aac.28.5.648. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Kutzer E., Oittner R., Leodolter S., Brammer K. W. A comparison of fluconazole and ketoconazole in the oral treatment of vaginal candidiasis; report of a double-blind multicentre trial. Eur J Obstet Gynecol Reprod Biol. 1988 Dec;29(4):305–313. doi: 10.1016/0028-2243(88)90071-8. [DOI] [PubMed] [Google Scholar]
  4. Miles M. R., Olsen L., Rogers A. Recurrent vaginal candidiasis. Importance of an intestinal reservoir. JAMA. 1977 Oct 24;238(17):1836–1837. doi: 10.1001/jama.238.17.1836. [DOI] [PubMed] [Google Scholar]
  5. O'Connor M. I., Sobel J. D. Epidemiology of recurrent vulvovaginal candidiasis: identification and strain differentiation of Candida albicans. J Infect Dis. 1986 Aug;154(2):358–363. doi: 10.1093/infdis/154.2.358. [DOI] [PubMed] [Google Scholar]
  6. Odds F. C. Genital candidosis. Clin Exp Dermatol. 1982 Jul;7(4):345–354. doi: 10.1111/j.1365-2230.1982.tb02441.x. [DOI] [PubMed] [Google Scholar]
  7. Phillips R. J., Watson S. A., McKay F. F. An open multicentre study of the efficacy and safety of a single dose of fluconazole 150 mg in the treatment of vaginal candidiasis in general practice. Br J Clin Pract. 1990 Jun;44(6):219–222. [PubMed] [Google Scholar]
  8. Richardson K., Brammer K. W., Marriott M. S., Troke P. F. Activity of UK-49,858, a bis-triazole derivative, against experimental infections with Candida albicans and Trichophyton mentagrophytes. Antimicrob Agents Chemother. 1985 May;27(5):832–835. doi: 10.1128/aac.27.5.832. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Stein G. E., Christensen S., Mummaw N. Comparative study of fluconazole and clotrimazole in the treatment of vulvovaginal candidiasis. DICP. 1991 Jun;25(6):582–585. doi: 10.1177/106002809102500602. [DOI] [PubMed] [Google Scholar]
  10. Troke P. F., Andrews R. J., Brammer K. W., Marriott M. S., Richardson K. Efficacy of UK-49,858 (fluconazole) against Candida albicans experimental infections in mice. Antimicrob Agents Chemother. 1985 Dec;28(6):815–818. doi: 10.1128/aac.28.6.815. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Van Tyle J. H. Ketoconazole. Mechanism of action, spectrum of activity, pharmacokinetics, drug interactions, adverse reactions and therapeutic use. Pharmacotherapy. 1984 Nov-Dec;4(6):343–373. doi: 10.1002/j.1875-9114.1984.tb03398.x. [DOI] [PubMed] [Google Scholar]
  12. Van der Pas H., Peeters F., Janssens D., Snauwaert E., Van Cutsem J. Treatment of vaginal candidosis with oral ketoconazole. Eur J Obstet Gynecol Reprod Biol. 1983 Mar;14(6):399–404. doi: 10.1016/0028-2243(83)90209-5. [DOI] [PubMed] [Google Scholar]

Articles from Infectious Diseases in Obstetrics and Gynecology are provided here courtesy of Wiley

RESOURCES